Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients

Psychopharmacology
Eline R ZaaijerJ Booij

Abstract

Extended-release naltrexone (XRNT), an opioid receptor antagonist, is successfully used in the treatment of opioid dependence. However, naltrexone treatment of opioid-dependent patients may reduce striatal dopamine transporter (DAT) availability and cause depression and anhedonia. The aim of this study is to investigate changes in striatal DAT availability and symptoms of depression (Beck Depression Inventory (BDI)) and anhedonia (Snaith Hamilton Pleasure Scale (SHAPS)) before and during XRNT treatment. At baseline, ten detoxified heroin-dependent patients and 11 matched healthy controls underwent [(123)I]FP-CIT single photon emission computed tomography (SPECT) imaging to assess striatal DAT binding. Patients underwent a second SPECT scan 2 weeks after an intramuscular injection with XRNT. At baseline, the mean binding potential (BPND) in the putamen was at a trend level lower and the mean BDI score was significantly higher in heroin patients (n = 10) than in controls (n = 11) (3.45 ± 0.88 vs. 3.80 ± 0.61, p = 0.067, d = -0.48 and 12.75 ± 7.40 vs. 5.20 ± 4.83, p = 0.019, d = 1.24, respectively). Post hoc analyses in subgroups with negative urine analyses for opioids and cocaine showed significantly lower baseline putamen BPND ...Continue Reading

References

Jun 1, 1992·British Journal of Sports Medicine·M DanielJ Carter
Sep 1, 1991·British Journal of Addiction·T F HeathertonK O Fagerström
Oct 1, 1990·The Journal of Clinical Endocrinology and Metabolism·M R MurphyS L Lightman
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Aug 1, 1981·Drug and Alcohol Dependence·L E HollisterH K Gillespie
Jul 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·R P SnaithP Trigwell
Aug 1, 1997·Alcoholism, Clinical and Experimental Research·A C KingM J Kreek
Jul 14, 1998·Synapse·K A BergströmJ Tiihonen
Apr 3, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S J KishJ W Haycock
Apr 24, 2001·Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association·R C ArnauR Bramson
May 25, 2002·The American Journal on Addictions·Karen MiottoWalter Ling
Dec 14, 2002·Neuroscience and Biobehavioral Reviews·Martin R Yeomans, Richard W Gray
Mar 17, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maartje M L de WinJan Booij
Sep 6, 2006·Psychiatry Research·Marco SarchiaponeSergio De Risio
May 24, 2007·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Robert B InnisRichard E Carson
Oct 31, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Jan Booij, Paul Kemp
Dec 14, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fleur ZijlstraIngmar H A Franken
Dec 25, 2007·Annual Review of Psychology·George F Koob, Michel Le Moal
Feb 20, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Erik BootThérèse A van Amelsvoort
Aug 26, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Francesco RoselliPaolo Livrea
Mar 6, 2010·Annals of the New York Academy of Sciences·Kyle C Schmitt, Maarten E A Reith
Mar 13, 2010·Current Opinion in Psychiatry·Evgeny M Krupitsky, Elena A Blokhina
Dec 31, 2010·The American Journal of Drug and Alcohol Abuse·David J MyselsMaria A Sullivan
Jan 29, 2011·Annals of the New York Academy of Sciences·David R Gastfriend
Feb 11, 2011·Synapse·Kirsty DanielsonBronwyn M Kivell
May 11, 2011·CNS Neuroscience & Therapeutics·Philipp P LobmaierHelge Waal
Aug 24, 2013·Trends in Pharmacological Sciences·Roxanne A Vaughan, James D Foster

❮ Previous
Next ❯

Citations

Oct 30, 2016·Neuroscience and Biobehavioral Reviews·Kathryn BiernackiPeter G Rendell
Dec 26, 2016·Peptides·Richard J Bodnar
Mar 30, 2018·The American Journal on Addictions·Adam BisagaThomas R Kosten
Mar 21, 2017·European Journal of Nuclear Medicine and Molecular Imaging·E ZoonsJ Booij
Sep 7, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Felicia KampJoseph Kambeitz
Jun 11, 2019·Frontiers in Psychiatry·Marianne DestoopGeert Dom
Feb 12, 2020·Clinical Psychological Science : a Journal of the Association for Psychological Science·Brian D KilukMehmet Sofuoglu
Jan 10, 2020·Annual Review of Pharmacology and Toxicology·Moriah L JacobsonIrwin Lucki
Jan 9, 2020·Harvard Review of Psychiatry·Caroline A BrowneIrwin Lucki
Mar 23, 2021·Current Addiction Reports·Mina M RizkBarbara Stanley

❮ Previous
Next ❯

Software Mentioned

Statistical Package for the Social Sciences ( SPSS )
Neurofocus

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.